BRIEF-Rocket Pharmaceuticals Receives EMA Priority Medicines Designation For RP-L201 Gene Therapy
BRIEF-Rocket Pharmaceuticals Receives EMA Priority Medicines Designation For RP-L201 Gene Therapy
简介-Rocket PharmPharmticals获得EMA RP-L201基因治疗优先药物称号
March 29 (Reuters) - Rocket Pharmaceuticals Inc :
* ROCKET PHARMACEUTICALS RECEIVES EMA PRIORITY MEDICINES (PRIME) DESIGNATION FOR RP-L201 GENE THERAPY FOR TREATMENT OF LEUKOCYTE ADHESION DEFICIENCY-I
* ROCKET PHARMACEUTICALS - LOOK FORWARD TO SHARING INITIAL PHASE 2 DATA FROM POTENTIALLY REGISTRATION-ENABLING LAD-I TRIAL IN Q2 OF 2021
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
* ROCKET PHARMACEUTICALS RECEIVES EMA PRIORITY MEDICINES (PRIME) DESIGNATION FOR RP-L201 GENE THERAPY FOR TREATMENT OF LEUKOCYTE ADHESION DEFICIENCY-I
* ROCKET PHARMACEUTICALS - LOOK FORWARD TO SHARING INITIAL PHASE 2 DATA FROM POTENTIALLY REGISTRATION-ENABLING LAD-I TRIAL IN Q2 OF 2021
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
March 29 (Reuters) - Rocket Pharmaceuticals Inc :
* ROCKET PHARMACEUTICALS RECEIVES EMA PRIORITY MEDICINES (PRIME) DESIGNATION FOR RP-L201 GENE THERAPY FOR TREATMENT OF LEUKOCYTE ADHESION DEFICIENCY-I
* ROCKET PHARMACEUTICALS - LOOK FORWARD TO SHARING INITIAL PHASE 2 DATA FROM POTENTIALLY REGISTRATION-ENABLING LAD-I TRIAL IN Q2 OF 2021
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
路透3月29日电-火箭制药公司(Rocket PharmPharmticals Inc):*火箭制药公司获得EMA优先药物(PRIME)称号,用于RP-L201基因疗法治疗白细胞粘附缺陷-I*火箭制药-期待在2021年第二季度分享可能注册的LAD-I试验的初始第二阶段数据Eikon的源文本:进一步的公司报道:(Reurs.Briefs@thomsonreurs.com;)
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
风险及免责提示
以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
知道了
风险及免责提示
以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
知道了
抢沙发
0 0 0
赞大爱笑哭社会社会Emm心碎怒
轻触选择心情
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧
点击这里分享给好友
暂无评论,快来抢沙发吧!